Tumour Necrosis Factor-Alpha Expression in Segmental Colitis Associated with Diverticulosis Down-Regulates After Treatment

Abstract

Background & Aims: Tumour Necrosis Factor-α (TNF-α) expression may be increased in Segmental Colitis Associated with Diverticulosis (SCAD). Our aim was to assess TNF-α expression in SCAD in relationship to the treatment.

Methods: 10 patients affected by severe (type B and  D) SCAD were studied (6 males, 4 females, mean age 60.54 years, range 43-85 years). All patients were treated with beclomethasone dipropionate 10 mg/day plus a probiotic preparation VSL#3 for 8 weeks. At that time, clinical, endoscopic and histological reassessment was performed. Controls were 5 patients with active ulcerative colitis (UC).

Results: After treatment, all SCAD B and no SCAD D patients were  in remission. The TNF-α expression dropped from 42.7% (±7.58) to 15.7% (±2.6) in SCAD B patients (p=0.001), and from 40% (±5.9) to 28.6% (±5.3) in SCAD D patients (p=0.005). In UC patients, the TNF-α expression dropped from 45.5% (±5.09) to 22.5% (±2.5) (p=0.001). Neither SCAD B nor SCAD D patients showed a significant difference in TNF-α expression compared to UC after treatment. Finally, TNF-α was significantly overexpressed in SCAD D than in SCAD B at the end of treatment (p=0.048).

Conclusions: TNF-α expression in SCAD down regulates after treatment, and seems to be related to the clinical response to therapy. This behaviour, similar to that of Inflammatory Bowel Diseases (IBD), confirms that this disease should be considered as a subtype of IBD.